149980.Kq
The company designs, develops, and sells advanced medical equipment and technology, primarily generating revenue through the sale of diagnostic imaging systems and related services.
Business. The company designs, develops, and sells advanced medical equipment and technology, primarily generating revenue through the sale of diagnostic imaging systems and related services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company designs, develops, and sells advanced medical equipment and technology, primarily generating revenue through the sale of diagnostic imaging systems and related services.
The company maintains a strong liquidity position, with a current ratio of 12.95, indicating a significant buffer of current assets relative to current liabilities. The debt-to-equity ratio is 0.02, suggesting a conservative capital structure with minimal reliance on debt financing. Free cash flow stands at 2,404,561,310 KRW, supporting operational flexibility and potential reinvestment.
Profitability metrics show a return on equity of 4.98% and a return on assets of 4.44%, which are below the industry median for ROE and ROA in the Advanced Medical Equipment & Technology sector. This suggests the company is underperforming relative to its peers in terms of capital efficiency and asset utilization.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic shifts and regulatory changes. No material revenue concentration by geography is reported, but the absence of geographic breakdown limits visibility into potential regional risks.
The company's revenue growth is expected to remain stable, with no significant changes in the current or next fiscal year. Historical revenue of 32,086,031,400 KRW aligns closely with the analyst estimate of 31,628,770,000 KRW, indicating a consistent performance trajectory. However, the absence of disclosed growth initiatives or new product launches limits visibility into future expansion.
Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong equity position reduce financial risk. No dilution pressure is expected in the near term, and no recent equity issuance or ATM/shelf registration activity has been reported.
Recent events include the latest financial filing, which shows stable revenue and profitability. No material changes in management, strategy, or regulatory environment have been disclosed. The company's operating cash flow is negative at -88,093,850 KRW, but this is offset by strong free cash flow and capital expenditure of -2,363,816,320 KRW, indicating ongoing investment in infrastructure.
- The company has a strong liquidity position with a current ratio of 12.95 and minimal debt.
- Return on equity and return on assets are below industry medians, indicating underperformance in capital efficiency.
- Revenue is concentrated in a single business segment with no geographic diversification.
- No immediate liquidity or dilution risks are present, and no recent equity issuance has been reported.
- Revenue growth is expected to remain stable, with no significant changes in the current or next fiscal year.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 149980.KQ Market data — financials · 2026-05-26
- Hironic Co Ltd Market data — analyst estimates · 2026-05-26